Abstract 397P
Background
Chronic hepatitis B infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Despite the endorsement of semi-annual ultrasonography as HCC surveillance method by international societies in at risk population, the accurate prediction of HCC risk is important for public policy strategy in a limited-resource country. Thus, we aim to develop the scoring systems, which are individualized surveillance strategy and cost-effectiveness to assess the risk of HCC in patients with chronic hepatitis B.
Methods
This retrospective cohort study was conducted to develop a risk estimate model of HCC in chronic hepatitis B (CHB) patients. Our prediction model was derived from data obtained in 2,208 CHB patients from Chulabhorn Hospital, Thailand. (Follow-up period: 2011-2017). Forward stepwise multivariable parametric regression model was applied to obtain coefficients for each predictor. Model input included age, sex, liver cirrhosis, cigarette smoking, alcohol consumption, diabetes mellitus, body mass index, serum HBV DNA level, HBeAg status, alanine aminotransferase, aspartate aminotransferase (AST), alpha-fetoprotein and AST to platelet ratio index. Receiver operating characteristic curves were used to assess discriminatory accuracy of the model.
Results
During a median follow-up of 6.67 years, 20 cases of HCC were newly diagnosed. Age and liver cirrhosis were statistical significant independent predictors of HCC risk. In the bootstrap simulation (1000 random samplings), the corrected c-index was 0.75 (0.58-0.91). The HCC risk was calculated from the following formula: Age (<50 year = 0; 50-59 year = 1; ≥ 60 year = 2) + Cirrhosis (Yes = 4; No = 0). A 6-point risk score could predict HCC risk at 10 years, ranging from 1.95%, 18.29% and 56.96% in low- (score 0-2), medium- (score 4-5) and high-risk group (score 6).
Conclusions
A simple prediction score constructed from routine clinical and laboratory parameters are accurate in predicting HCC development in Thai patients with CHB infection. Individualized HCC surveillance strategy including surveillance interval and/or alternative surveillance test could be reasonable and cost effectiveness based on our risk scoring. Future prospective validation study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Teerapat Ungtrakul.
Funding
Chulabhorn Royal Academy.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract